Participant flow

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation · Source last updated 2021-10-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Velcade (Bortezomib) Thalidomide Dexamethasone Allocated to treatment (n=135) Received allocated treatment (n=135)

   id

   FG000

   title

   Thal + Dex + Velcade

2. description

   Standard treatment Thalidomide Dexamethasone Allocated to treatment (n=134) Received allocated treatment (n=134)

   id

   FG001

   title

   Thal + Dex

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         135

      2. group Id

         FG001

         num Subjects

         134

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         52

      2. group Id

         FG001

         num Subjects

         54

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         83

      2. group Id

         FG001

         num Subjects

         80

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

FPI 08-Jul-2005 LPI 21-Jun-2010

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice